Research and Markets: Chemistry, 2nd Edition Is Engineered To Cater For the Content Needs of the First Year Chemistry …

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/fd2rw3/chemistry_2nd_edi) has announced the addition of John Wiley and Sons Ltd's new book "Chemistry, 2nd Edition" to their offering.

The second edition of this market leading textbook, with a multimedia-integrated approach to the presentation of Chemistry for University students!

This is the second edition of this market leading text book. The text and digital package is engineered to cater for the content needs of the first year chemistry course as it is generally taught at universities.

The success of the 1st edition has been attributed to the student friendly and engaging writing style, the relevance to real life, and the clear worked examples; which all help demystify chemistry for the 1st year student. In addition to this, our online teaching and learning system, WileyPLUS which is fully integrated with the text, provides lecturers and students with an equitable multimedia platform to enhance their teaching and learning.

Following its success, the first edition was rigorously reviewed, and enhancements made to both the text and the digital resources. The 2nd edition has been enriched in both the text (by addition of new Main Groups chapter and other minor improvements).

New to this Edition:

- Chapter 2 has new content on dimensional analysis and errors and significant figures

- Chapter 8 has been broken into smaller sections allowing mathematical content to be ignored if not required

- NEW! Chapter 14 The p-block elements' - previously available as an additional supplement, this chapter has now been integrated into the text based on market demand

More:
Research and Markets: Chemistry, 2nd Edition Is Engineered To Cater For the Content Needs of the First Year Chemistry ...

Research and Markets: Clinical Chemistry – Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/w5vzp6/clinical_chemistry) has announced the addition of GlobalData's new report "Clinical Chemistry - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" to their offering.

GlobalData's new report, Clinical Chemistry - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 provides key data, information and analysis on the global clinical chemistry market. The report provides market landscape, competitive landscape and market trends information on the clinical chemistry market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

- Key segments covered include Clinical Chemistry Rapid Tests & POC, Enzyme Chemistry Reagents, Metabolite Chemistry Reagents, Electrolyte Chemistry Reagents, Clinical Chemisty Analyzers, and Urine Analysis.

- Annualized market revenues data from 2004 to 2011, forecast forward for seven years to 2018. Company shares data for 2011.

- Qualitative analysis of key market trends, market drivers, and restraints by each category within the clinical chemistry market.

- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.

- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Ortho-Clinical Diagnostics and Beckman Coulter, Inc.

Continue reading here:
Research and Markets: Clinical Chemistry - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

ASU creating new chemistry forensics study

Staff Writer

Jackie Ricciardi/staff Augusta State chemistry professor, Stephanie Myers poses for a photo in her office on Tuesday, May 15, 2012. She will be starting a new forensic science program.

Augusta State University is creating a new chemistry track for students who want to become behind-the-scenes scientists.

The Department of Chemistry and Physics will debut a forensic science track in fall 2012, which can lead to jobs testing blood stains on clothes from crime scenes or determining types of drugs found in the bloodstream.

We are a very hands-on department, said Stephanie Myers, professor of chemistry and forensic science advisor. Students get lots of real lab experience. Theyre not watching someone else do it.

Students who sign up for the new track will still graduate with a chemistry degree but with a concentration in the forensic field. ASU Vice President for Academic Affairs Carol Rychly said adding this track to the chemistry department compliments the goals of the merger with Georgia Health Sciences University - creating more options for students and producing more qualified graduates.

One of the things that were looking to as we move toward the new (university) is to build up the programs we already have and making them more robust, Rychly said. Its a win-win. Youre meeting the students needs and youre providing the community employable people.

Rychly said she expects other departments to add more tracks or programs within their field in the next few years. The expansion also provides a chance for collaboration between liberal arts and health sciences, like a possible medical humanities course in the works, she said.

Myers said the forensic track was born out of an interest from the students and opportunity after she received a certificate in forensic science from The University of Florida in 2010.

Students will take standard chemistry requirements their freshman and sophomore years and move toward more specialized forensic courses as upperclassmen.

Read the original here:
ASU creating new chemistry forensics study

Panel of Top Industry Executives to Discuss Biotech and Big Pharma – What’s Next? – 2012 BIO International Convention …

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today that a panel of top industry executives will discuss where biotech will be in the next ten years and how the pharmaceutical industry landscape is changing. With the biotech and pharmaceutical industries facing considerable challenges but also tremendous growth opportunities, attendees can expect to gain valuable insights into the future of biotech and big pharma.

Biotech and Big Pharma Whats Next? panelists include: Moderator: Joshua Boger, PhD, Founder and CEO (Retired), Vertex Pharmaceuticals Incorporated Panelists: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc; Christopher A. Viehbacher, Chief Executive Officer, Sanofi, Chairman, Genzyme and H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences

Wednesdays Keynote session is sponsored by Amgen, a leading human therapeutics company in the biotechnology industry.

Immediately preceding the Keynote panel, Senator John Kerry (D-MA) will address the 2012 BIO International Convention, this years global event for biotechnology, which will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA. Additionally, the Keynote will feature the presentation of awards for the Biotech Humanitarian of the Year and the Governor of the Year.

Senator Kerrys speech will address the major challenges to the life sciences innovation ecosystem. He is scheduled to speak Wednesday, June 20th at 12:00 p.m., during the Keynote luncheon.

Each year, we strive to provide attendees with a Keynote address by an industry thought leader to share their perspective on the state of the industry, said Robbi Lycett, Vice President of Conventions & Conferences at BIO. We anticipate Senator Kerry will continue this tradition and share his insights and vision for the future with our attendees.

John Kerry was elected to the United States Senate in 1984 and he has won reelection four-times since. He is now serving his fifth term. Senator Kerry has fought to protect our natural environment and has proved to be a leader on the global AIDS issue and confronting the climate crisis.

In 2003, Senator Kerry announced that he would be a candidate for President of the United States and he went on to mount a come from behind campaign that won the Democratic nomination and was nearly elected President.

Today, Senator Kerry is the tenth most senior Senator and the second longest serving Senator in his seat. He is chairman of the Foreign Relations Committee as well as holds a senior position on the Finance, Commerce and Small Business Committees.

See the original post:
Panel of Top Industry Executives to Discuss Biotech and Big Pharma – What’s Next? – 2012 BIO International Convention ...

Angel Biotechnology – Angel signs new contract with ReNeuron

16 May 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Angel signs new contract with ReNeuron to provide GMP (KOSDAQ: 018290.KQ - news) cell manufacturing services for completion of stroke clinical trial

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group (Berlin: RQE.BE - news) plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.

Dr Stewart White, Acting CEO, Angel Biotechnology (Berlin: A3G.BE - news) said: "Angel is very proud to be providing ReNeuron with additional manufacturing support to complete this ground breaking Phase 1 clinical trial. This contract is further recognition of the strong partnership between Angel and ReNeuron, and also reaffirms both companies commitment to provide solutions for a real clinical need."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director http://www.angelbio.com

Read the rest here:
Angel Biotechnology - Angel signs new contract with ReNeuron

Plandai Biotechnology, Inc. Announces Preliminary Agreement With Agriculture Giant, ZZ2, to Produce Highly …

SEATTLE, May 16, 2012 (GLOBE NEWSWIRE) -- Plandai Biotechnology, Inc. (OTCBB:PLPL.OB - News), a producer of highly bioavailable botanical extracts, today announced a preliminary agreement with ZZ2, a private farming conglomerate in Southern Africa and the largest producer of fresh tomatoes in the continent of Africa. Based on a long-standing working relationship, Dunn Roman Holdings Africa (Pty) Limited, a subsidiary of Plandai, will, under a new contract, acquire tomato waste from ZZ2 which will be processed to recover highly bioavailable antioxidants using the company's exclusive Hydrodynamic Extraction System.

Plandai Chairman and Chief Executive Officer, Roger Duffield, commented, "As with green tea catechin extract, our hydrodynamic system converts the tomato carotenoid isomers into a highly bioavailable product. This partnership with ZZ2 is especially advantageous because it gives us an extremely inexpensive and readily available source material throughout the year. With an initial agreement to acquire 30 tons of tomato waste per day, we can yield substantial volumes of carotenoids (lycopene, phytoene and phytofluene). With the current market price for even poorly-absorbed lycopene at $3,000/kg, this opportunity could add in excess of $700,000 in monthly revenues.

Discussing the timing of commencing production of these carotenoids, Mr. Duffield added, "A huge portion of our prior research has been in this field and has already been validated through a USDA study. As shown in the recent publication by Dr. Ishida in Food Chemistry--Effects of a Hydrodynamic Process on Extraction of Carotenoids from Tomato--Plandai's extraction process has already demonstrated the ability to deliver highly bioavailable carotenoids in numerous studies undertaken in conjunction with the California tomato processing industry and the USDA. In addition, unlike our green tea catechin extract, there will be no delay in getting raw materials ready for extraction. ZZ2 has an ample and ready supply of tomato waste available 365 days a year. We therefore anticipate that the tomato carotenoid extracts could actually come to market well ahead of our green tea gallate extract and bring us one step closer to becoming the world's largest supplier of highly bioavailable botanical extracts from live plant materials."

For additional information on ZZ2, visit http://www.zz2.biz. A memorandum of Understanding is under review by the respective attorneys and is expected to executed shortly. "Effects of a hydrodynamic process on extraction of carotenoids from tomato" Betty K. Ishida, Mary H. Chapman, United States Department of Agriculture, Food Chemistry 132 (2012) 1156--1160

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principle holdings consist of land, farms and infrastructure in South Africa. Web site: http://www.plandaibiotech.com/

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Read the original:
Plandai Biotechnology, Inc. Announces Preliminary Agreement With Agriculture Giant, ZZ2, to Produce Highly ...

Celldex Therapeutics Added to Nasdaq Biotechnology Index

NEEDHAM, Mass.--(BUSINESS WIRE)--

Celldex Therapeutics, Inc. (NASDAQ: CLDX - News) today announced that the Company will be added to the NASDAQ Biotechnology Index (NBI), effective prior to market open on Monday, May 21, 2012. The NBI includes biotechnology or pharmaceutical companies listed exclusively on the NASDAQ Global Select Market or on the NASDAQ Global Market that meet predetermined eligibility requirements, including a minimum market capitalization of $200 million and an average daily trading volume of at least 100,000 shares, amongst other criteria.

The index is ranked semi-annually in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq:IBB - News). In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges. For more information about the NBI, including eligibility criteria, visit https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf.

About Celldex Therapeutics, Inc.:

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Companys strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut (CDX-110), CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127, CDX-301, Belinostat and other products. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we initiated in 2011 and plan to initiate in 2012; our ability to adapt APC Targeting TechnologyTMto develop new, safe and effective vaccines against oncology and infectious disease indications; our ability to successfully complete product research and further development of our programs; the uncertainties inherent in clinical testing; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage research and development efforts for multiple products at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our limited cash reserves and our ability to obtain additional capital on acceptable terms, or at all; our ability to protect the Companys intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Companys products; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-K for the fiscal year endedDecember 31, 2011, anditsForms 10-Q and 8-K.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

See the article here:
Celldex Therapeutics Added to Nasdaq Biotechnology Index

Infinity Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI - News) today announced that the company will be added to the NASDAQ Biotechnology Index (NBI). The semi-annual re-ranking of the index will become effective prior to market open on Monday, May 21, 2012.

Our inclusion in the NASDAQ Biotechnology Index underscores the strength of our pipeline and our progress toward creating a sustainable, fully integrated biotechnology company, stated Adelene Q. Perkins, president and chief executive officer of Infinity. With six clinical trials ongoing across our three development programs, and the financial strength to execute them, we have the potential to meaningfully impact patients' lives while creating long-term value for shareholders.

The NBI was launched in 1993 and includes securities of biotechnology and pharmaceutical companies listed on the NASDAQ that meet minimum requirements, including market value and average daily share volume, among other criteria. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology IndexSM Fund (Nasdaq:IBB - News). For more information about the NASDAQ Biotechnology Index, including detailed eligibility criteria, visit https://indexes.nasdaqomx.com/.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative drug discovery and development company seeking to discover, develop and deliver to patients best-in-class medicines for diseases with significant unmet need. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinitys programs focused on the inhibition of the Hedgehog pathway, heat shock protein 90 and phosphoinositide-3-kinase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the companys website at http://www.infi.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the companys current expectations. For example, there can be no guarantee that Infinitys strategic alliance with Mundipharma International Corporation Limited will continue for its expected term or that it will fund Infinitys programs as agreed, that any product candidate Infinity is developing will successfully complete necessary preclinical and clinical development phases, or that development of any of Infinitys product candidates will continue. Further, there can be no guarantee that any positive developments in Infinitys product portfolio will result in stock price appreciation. Managements expectations could also be affected by risks and uncertainties relating to: Infinitys results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Infinitys ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures, including in connection with business development activities; development of agents by Infinitys competitors for diseases in which Infinity is currently developing its product candidates; and Infinitys ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing. These and other risks which may impact managements expectations are described in greater detail under the caption Risk Factors included in Infinitys quarterly report on Form 10-Q for the quarter ended March 31, 2012, filed with the Securities and Exchange Commission on May 8, 2012. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the original here:
Infinity Added to NASDAQ Biotechnology Index

NanoInk Expands Presence in Japan With Prestigious New Distributor

CHICAGO, IL--(Marketwire -05/15/12)- The NanoFabrication Systems Division of NanoInk is pleased to announce that it has reached a non-exclusive agreement with the Research Institute of Biomolecule Metrology Co., Ltd. (RIBM) to serve as a distributor in Japan. RIBM will distribute NanoInk's desktop nanofabrication equipment, including the NLP 2000 System and the DPN 5000 System, which has a wide range of applications ranging from nanoarray-based protein analysis to nano-bioengineering and biomaterial research. As a leader in the visualization and measurement of biomolecules, RIBM aims to spearhead technological advancements in the field of nano-biotechnology.

"RIBM is a leading player in the Japanese nano-biology industry and has already established a strong relationship with NanoInk's target customers in Japan. Its sales and technical teams have the in-depth knowledge required to understand the scientific instrument market and it has proven expertise in selling technically-sophisticated equipment into that space. With these strengths, RIBM is the ideal partner for driving sales of NanoInk's unique nanofabrication platforms for use in life science and bioengineering applications," said Oliver Yeh, General Manager, NanoInk's NanoFabrication Systems Division, Asia-Pacific region. "We look forward to a close and successful long-term partnership with RIBM as we expand our reach in Japan by promoting the unique capabilities and benefits of the NanoInk line of patterning systems."

"We are delighted to be appointed as a distributor for NanoInk's products in Japan's life science and bioengineering markets," said Dr. Takashi Morii, Director of the Biomolecule Metrology Division at RIBM. "NanoInk's product lines are complementary to our current product portfolio and are attractive to our targeted nano-biotechnology markets. We look forward to working with the NanoInk team."

NanoInk's NanoFabrication Systems Division brings sophisticated nanofabrication to the laboratory in an easy to use and affordable platform. NanoInk's NLP 2000 System is a desktop instrument that allows researchers to rapidly design and create custom engineered and functionalized surfaces by using Dip Pen Nanolithography (DPN) to transfer minute amounts of materials over a large, environmentally controlled work area. With the ability to create custom patterns of nano-to-microscale features in under an hour, the NLP 2000 System is valuable for protein and biomolecular patterning, microstructure and biosensor functionalization, cell biology and polymer printing applications.

The DPN 5000 System is a full-featured, dedicated instrument for versatile nanopatterning of a variety of materials with nanoscale accuracy and precision. With its user-friendly interface, it is possible to easily design complex patterns while also precisely controlling tip movements during the writing process. The DPN 5000 System is the ideal platform for nanofabrication, nanomaterials and biomaterials applications that exhibit nanoscale printing, imaging and registration requirements.

With locations in Tsukuba, Tokyo, and Hiroshima, RIBM specializes in biomolecule metrology, molecular imaging and food & environmental analysis applications. It develops, manufactures, and sells SPM equipment and conducts contract measurement services using SPM. In addition, it manufactures and sells high-speed AFM for biology which can capture movie images of moving molecules. RIBM also markets nano-measurement equipment and inspects food and environmental samples for genetic modifications, allergens, viruses and residual agricultural chemicals.

To obtain more information or to place an order through RIBM for NanoInk's desktop nanofabrication systems, please email Dr. Takashi Morii at morii@ribm.co.jp. More background on RIBM is available at: http://www.ribm.co.jp/index-e.htm.

For information on additional NanoInk distributors, visit: http://nanoink.net/distributors.html. More detail about the NanoFabrication Systems Division of NanoInk is available at: http://www.nanoink.net/divisions.html#NanoFabrication.

About NanoInkNanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography (DPN), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has several divisions including the NanoFabrication Systems Division, the Nano BioDiscovery Division, the NanoProfessor Division and the NanoGuardian Division. For more information on products and services offered by NanoInk, Inc., visit http://www.nanoink.net.

NanoInk, the NanoInk logo, Dip Pen Nanolithography, DPN, and NanoProfessor are registered trademarks of NanoInk, Inc.

Excerpt from:
NanoInk Expands Presence in Japan With Prestigious New Distributor

Research and License Agreements between National Cheng Kung University and Novo Nordisk A/S

TAINAN, Taiwan--(BUSINESS WIRE)--

A southern Taiwan-based National Cheng Kung University (NCKU) research team led by Ming-Shi Chang, NCKU professor of the Department of Biochemistry and Molecular Biology, has discovered an anti-interleukin-20 (anti-IL-20) antibody, a potential new anti-osteoporosis and anti-rheumatoid arthritis drug, and agrees to license selected intellectual property and transfer certain technology to Novo Nordisk A/S, a Danish-based pharmaceutical company for a total payment of US$ 13.3 million in case of a successful completion of the project.

In addition, Professor Ming-Shi Chang and Novo Nordisk A/S have established a 2-year research collaboration to further strengthen and possible expand the usages of an IL-20 antibody.

NCKU President Hwung-Hweng Hwung hailed the groundbreaking discovery of anti-interleukin-20 antibody: The findings not only mark a milestone in global healthcare, but also raise the visibility of Taiwans academic research.

This medical discovery was published in the Journal of Experimental Medicine (JEM) and has drawn huge attention in the academic world and the biotechnology industry as well.

IL-20 has a key role in osteoclast differentiation, and blockading this cytokine could represent a novel therapeutic approach for osteoporosis, according to data from the NCKU medical team.

The chief editor of Nature Reviews wrote a research highlight in the September issue of Nature Reviews Rheumatology commenting on this finding, while Science-Business eXchange (SciBX) published a cover story reporting on the discovery in the same month.

The study not only signifies groundbreaking findings in the pathogenesis of osteoporosis, but could lead to the innovation of new drugs to treat osteoporosis and rheumatoid arthritis.

Professor Chang pointed out that the medical expense of anti-osteoporosis drugs for patients around the world is estimated to be as much as US$8 billion per year, and that the amount spent on them by 2015 will be about US$8.8 billion.

Changs team has discovered that IL-20 is an important factor in bone cell differentiation and that high serum IL-20 levels in osteoporosis patients cause bone destruction.

See the original post here:
Research and License Agreements between National Cheng Kung University and Novo Nordisk A/S

Global Laboratory Chemical Reagents Industry

NEW YORK, May 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Laboratory Chemical Reagents Industry

http://www.reportlinker.com/p087339/Global-Laboratory-Chemical-Reagents-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

This report analyzes the worldwide markets for Laboratory Chemical Reagents in US$ Million by the following Product Segments: Molecular Biology (Monoclonal & Polyclonal Antibodies, Gene Expression, Vectors, Cloning, & Sequencing, Gene Synthesis, Extraction Kits, PCR Reagents, Enzymes, & Others), Biochemistry (IVD), Cytokine & Chemokine Testing, Cell/Tissue Culture, Carbohydrate Analysis, Immunohistochemistry, and Environmental Testing (Pesticide Residues, & Others). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 226 companies including many key and niche players such as BD Biosciences, Beckman Coulter, Inc., Biomerieux, EMD Chemicals Inc., GE Healthcare, Life Technologies Corporation, Meridian Life Science, Inc., PerkinElmer, Inc., SAFC Biosciences, Inc., Shimadzu Biotech, Sigma-Aldrich Corp., Takara Bio, Inc., Wako Pure Chemical Industries Ltd., and Waters Corp. Major Monoclonal and Polyclonal Antibodies suppliers also profiled in the report include Strategic Diagnostics Inc., Gallus Immunotech, Inc., and Lonza Biologics Ltd., key Nucleic Acid Extraction Kits supplier, Quiagen, is also profiled in the report. The two major Biochemistry Reagents and Related Chemical Suppliers highlighted in the report are A.G. Scientific, Inc., and Promega Corporation. R&D Systems, the major Cytokine and Chemokine Reagent and Kits supplier, is also profiled in the report. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

See the original post here:
Global Laboratory Chemical Reagents Industry

John Joseph Scocca, Hopkins biochemistry professor

John Joseph Scocca, a retired Johns Hopkins biochemistry professor recalled for his keen critical eye, died of chronic obstructive pulmonary disease May 10 at Gilchrist Hospice Care in Towson. He was 72 and lived in Aberdeen.

Born in South Philadelphia, he came to Baltimore in 1958 as a Johns Hopkins University undergraduate and went on to spend his entire career at the school. He earned a bachelor's degree in three years and received a doctorate in biochemistry. He then became a professor at what is now the Bloomberg School of Hygiene and Public Health, where he retired four years ago.

Family members said that in his third year of graduate school, he taught laboratory technique to a group of students that included his future wife, Jane Ruble.

They moved to a home on Monterey Road in Ednor Gardens north of the old Memorial Stadium. He, his wife and children were Orioles fans and enjoyed attending games. In 1977, the family moved to Aberdeen.

Colleagues said that as a professor at the School of Public Health, he taught biochemistry to graduate students from outside the biochemistry department. He called his course "baby biochemistry," but friends said he was a thorough and demanding scientist-teacher. He also valued concise speaking and brevity.

"Perhaps John's most significant contributions involved his 30-year tenure as chief organizer of the laboratory rotations for first-year doctoral students," said a Hopkins colleague, Roger McMacken, who lives near Lake Roland. "John operated a dreaded alarm clock that so loudly, rudely and famously halted student rotation talks precisely 10 minutes after the start of any still-continuing research presentation."

Mr. McMacken said this was an "immensely effective training strategy." By the time the students returned for more oral presentations, they "were virtually all completed before the sound of the jarring alarm clock."

He recalled his favorite "Scocca moment," which involved the annual opening day meeting of the department faculty with an incoming class of doctoral students.

"John, because of his wit, keen sense of humor, candor, and unparalleled scientific integrity, routinely had the honor of describing the department's academic program for first-year students," said Mr. McMacken. "What followed was an impassioned exhortation about the do's and don'ts of laboratory research and academic life. No one, including John, knew precisely what he was going to say. But you could certainly count on 45 minutes of a hilarious, off-the-cuff soliloquy that perpetually was a highlight of academic life for us."

Family members said that his personal research work involved the study of the bacterium Haemophilus influenzae and its interactions.

Visit link:
John Joseph Scocca, Hopkins biochemistry professor

App Wrap: 'Leonardo Da Vinci: Anatomy,' 'Blueprints 3D'

To view our videos, you need to enable JavaScript. Learn how. install Adobe Flash 9 or above. Install now. Then come back here and refresh the page.

There's a good chance you've seen the drawings of Leonardo da Vinci, but now a new app lets people fully appreciate what makes them so amazing. The "Leonardo da Vinci: Anatomy" app lets users pour over every single one of his 268 detailed drawings of the human body.

They can zoom in to see just how detailed Leonardo got, and some of the drawings have even been turned into 3-D models, for users to better understand just how well he understood anatomy more than 500 years ago.

If that doesn't help, there are also expert interviews to lay out why they are so impressed with how accurate his sketches are.

Users can also get close on his well-documented "mirror image" notes, view them with a virtual mirror and translate them.

"Leonardo da Vinci: Anatomy," which was created to coincide with an exhibit of his drawings at the Queens Gallery in Buckingham Palace, is an iPad app for $13.99.

From blueprints of the human body to actual blueprints, there is now a game called "Blueprints 3D." Users choose a category from architecture to electronics to space to animals.

What they then see as they begin a level is a bunch of scattered lines, and the goal is to twist and rotate the lines so that they are in the perfect place to recreate a blueprint of something, from the Statue of Liberty to a hamster. Users do not know what it is they are done.

There are three levels that make the app increasingly harder.

"Blueprints 3D" is an iOS app that, for a limited time, is just 99 cents.

The rest is here:
App Wrap: 'Leonardo Da Vinci: Anatomy,' 'Blueprints 3D'

Who survives 'Grey's' finale plane crash?

ABC

By Lesley Goldberg, The Hollywood Reporter

"Grey's Anatomy" viewers, buckle up: you're in for screams, blood, exposed bones and a completely stressful episode if the first six minutes of Thursday's Season 8 finale are any indication of what's coming.

STORY: "Grey's Anatomy's" Shonda Rhimes on the deadly finale: "We're literally saying goodbye to people"

After a plane carrying some of Seattle Grace's best and brightest crashed into a forest, Meredith (Ellen Pompeo), Derek (Patrick Dempsey), Cristina (Sandra Oh), Lexie (Chyler Leigh), Mark (Eric Dane) and Arizona's (Jessica Capshaw) lives were left hanging in the balance.

STORY: "Grey's Anatomy": Sarah Drew on the boards, April and Jackson's steamy hook-up and the finale "event"

Showrunner Shonda Rhimes has warned that the episode, fittingly titled "Flight," will include what she calls a "pretty big death."

STORY: "Grey's Anatomy" Recap: Whose lives are hanging in the balance?

"We're not talking [about] some guest star [who] is going to come in and die kind of thing; it's a big death and it's fairly shocking," she told The Hollywood Reporter during a recent interview. "It was hard, it was hard to write, it was hard to listen to at the table read. It is a difficult thing to do and not done lightly. When one of your main characters dies, it always affects the heart and soul of the hospital."

So who will survive the first six minutes? Watch the clip to find out, but be warned: it's graphic and severely cringe-inducing.

Excerpt from:
Who survives 'Grey's' finale plane crash?

Greece: The anatomy of a default

FORTUNE -- Everyone from Greece's squabbling political parties to Europe's central bankers are expressing faith that Greece will remain in the Euro. That's not surprising, since simply talking about how to manage an exit would spread panic, making the exit inevitable. But the panic is already here. Greece's departure from the Euro could happen within a couple of weeks, if not a few days.

The pressing problem isn't a splintered legislature that may balk at delivering the reforms that the IMF and European Community are demanding in exchange for the next tranche of bailout money. It's a disastrous, old-fashioned run-on-the bank. "For a year, Greeks have been sending their savings from Greek banks to foreign banks," says Robert Aliber, retired professor of international economics from the University of Chicago. "Now, the flood has reached a crescendo." Indeed on Monday alone, outflows from the Greek banks reached almost $900 million.

The flight of capital is sapping the deposits needed to refinance mortgages and small business loans, causing a full-blown credit crisis. Greeks are also extremely reluctant to spend their Euros on cars, dining or anything else, since they reckon those Euros will buy more at the supermarkets and auto lots in the weeks or months ahead. The disappearing consumer is further crippling the economy.

MORE: 'Austerity' isn't an evil word

Greece's exit is absolutely necessary. "Its prices and costs are far too high under the Euro, so it just cannot compete on international markets," says Aliber. "The Greeks have suffered far more through all these misguided bailouts than they've gained by lowering prices or costs." The political gridlock, argues Aliber, is actually a good thing because it will hasten abandoning a disastrously overvalued currency, just what's needed to get Greece growing again.

The mechanics of shelving the Euro for its own currency are pretty predictable. One day soon, imagine it's late on a Friday afternoon, the Greek government will declare all banks closed for the following week. By Monday, the legislature will vote an emergency law that designates a fixed exchange rate of, say, 1 drachma the Greek pre-Euro currency for each Euro. By Monday, all corporate and personal savings in Greek banks will be denominated in drachma.

The drachma will tumble in value, so that almost immediately, Greek consumers will need at least 1.5 Drachma to buy one Euro. A savings account that held 15,000 euros is now 15,000 Drachma. But those drachmas will soon fetch just 10,000 Euros. That's a "devaluation" of 33%. "That number is the low-end of the range for countries that exit a common currency," says Uri Dadush, an economist at the Carnegie Endowment.

What happens next is the pivotal issue, and top economists disagree strongly on Greece's post-Euro future. To be sure, this isn't a play by Aeschylus or Aristophanes where the audience knows the finale. Yanis Varoufakis of the University of Athens foresees a Greek tragedy in which a run on the banks is followed by a run on the drachma. "Greeks paid in drachma will go to the ATM then immediately exchange their drachma for Euros people have stashed in their freezers," says Varoufakis. He thinks that the drachma will keep plunging against foreign currencies, and Greeks will keep bailing, causing a new crisis of hyperinflation.

MORE: The 3 biggest benefits of producing more oil

But the disaster scenario isn't inevitable. "Other countries have left what's effectively a common currency zone without suffering hyperinflation," says Hans Humes, president of investment firm Greylock Capital, which holds Greek government bonds. Aliber thinks that Greece's exit will create the same growth dynamic that's recharged Iceland and Argentina, both of whom effectively shed overvalued currencies.

See the article here:
Greece: The anatomy of a default

'Grey's Anatomy' Finale: Bloody Season 8 Sneak Peek (VIDEO)

MONDAY, MAY 14: "Bones"

"Bones" (8 p.m. ET on Fox) season finale
Evil tech genius Christopher Pelant (guest star Andrew Leeds), a suspect in a previous case Brennan and Booth handled, is back in court on appeal. Knowing what he is capable of, Brennan and Booth inform the judge that he is a suspect in two murder cases. Then, Brennan and Booth are called to the scene of a new murder. After determining the victim is Brennan's friend, who also is linked to Pelant, the Jeffersonian team works to prove he is guilty once and for all. But when law enforcement examines the team's findings, key pieces of evidence are tied to Brennan and suspicion falls on her.

"Gossip Girl" (8 p.m. ET on The CW) season finale
When Gossip Girl goes after Blair as she's never done before, Serena admits she may have unintentionally played an important role in Blair's latest nightmare. Meanwhile, Nate invites Lola to move in with him, and Lily must make a big decision about the future of her marriage. Finally, by episode's end, Blair will make a choice between the two men in her life ... will it be Chuck or will it be Dan? Followed by the finale of the also-renewed "Hart of Dixie."

"How I Met Your Mother" (8 p.m. ET on CBS) one-hour season finale
On Barney's future wedding day, when his wife is finally revealed, the gang reminisces about the time they encouraged Ted to follow his heart and go after the one that got away. Followed by the season finales of "Two and a Half Men" and "Hawaii Five-0."

"Make It or Break It" (9 p.m. ET on ABC Family) series finale
Eight weeks at the USA Training Center have led to this moment: who will make it onto the 2012 Olympic Gymnastics team and who will be left behind in the show's final episode. Payson decides to rework her floor routine at the risk of losing a spot on the team. Kaylie is at a loss when Jordan refuses her help. Still recovering from surgery, Lauren balances her health with her need to make it to the Olympics. Meanwhile, Kaylie is thrown for a loop when she is told that her drug test came back positive for a banned substance.

"The Bachelorette" (9.30 p.m. ET on ABC) season premiere
Fan-favorite Emily Maynard -- the first single mother in "Bachelorette" history -- begins her own search for love in Charlotte, NC in the eighth edition of the romance reality series. Season highlights include trips to Bermuda, London, Dubrovnik and Prague, and appearances from Dolly Parton, Gloriana, Luke Bryant and The Muppets.

"Kurt Sutter's Outlaw Empires" (10 p.m. ET on Discovery) series premiere
"Sons of Anarchy" creator Kurt Sutter enters the realm of the gangs and families who have dominated our streets and helped shape our nation's history. Steered by Sutter's compelling insight, each episode tells the complete story of an iconic American outlaw dynasty -- directly from the mouths of people from the inside. Through their no-holds-barred accounts, the series takes an unvarnished look at moment-by-moment experiences that were not only pivotal for the organizations themselves, but life-changing for the individuals telling the stories.

"Smash" (10 p.m. ET on NBC) season finale
The big night is finally here. Tom and Julia race against time to save the show, while Derek makes a decision that will change the lives of Karen and Ivy forever. Ellis reveals his true colors (hmm) -- but when he finally makes his move to save "Bombshell," will it be for or against Eileen? In the midst of it all, another bombshell goes off -- this time in Karen and Dev's relationship.

"Glee" (8 p.m. ET on Fox) double-bill
As the countdown to graduation continues, the kids of New Directions prepare a high-concept routine for Nationals. When Tina bumps her head, the world of New Directions is turned upside down in her eyes. Then, the New Directions perform at Nationals for celebrity judge Lindsay Lohan (guest-starring as herself). Worth watching for the Lohan trainwreck factor alone, no?

"Cougar Town" (8 p.m. ET on ABC) double-bill
Now that the underappreciated (and still genius) comedy has officially made the move to TBS, ABC seems to be in burn-off mode with two weeks of hour-long blocks -- but we're just happy that it'll be around for another year. In the first episode, Grayson moves in with Jules after the hurricane damages his house, but the sudden togetherness makes them wonder if they're going to make the same mistakes in their upcoming marriage that they made in their past relationships. In the second, when Jules realizes that the cul-de-sac crew didn't celebrate Thanksgiving together, she decides to celebrate the holiday, even though it's spring. The "Private Practice" season finale airs at 10 p.m. ET.

Read more from the original source:
'Grey's Anatomy' Finale: Bloody Season 8 Sneak Peek (VIDEO)

Anatomy of a protest

Yesterday was a tumultuous day for Brisbane's indigenous community, from a pre-dawn eviction of a makeshift tent embassy at Musgrave Park in South Brisbane and impromptu protest marches through the city centre. Amy Remeikis was there to document the entire day, from beginning to end.

The police moved in just before dawn.

Musgrave Park at West End was surrounded by officers.

Advertisement: Story continues below

The media were directed to a staging point on the corner on Cordelia and Glenelg Streets, but getting there from the Cordelia Street side was difficult.

All side streets linking to the park were cordoned off, even for those on foot. While members of the media tweeted they were being escorted out of the tent embassy site, police were denying others entry.

Reaching the staging area required the showing of ID, both photo and a business card and following police directions to the letter; no, step back three steps please but once in the required area, the media were largely ignored.

For a while, nothing happened. Protesters came in support of the tent embassy members, establishing an area across the road from the park. A microphone and mobile speaker were quickly found. Speeches were made. Songs were sung. Across the road, those inside the fence erected around the embassy alternatively danced, cheered and yelled.

The sticking point in the negotiations was the sacred fire, started from embers from a similar fire at the Canberra tent embassy, where the idea for corresponding tent embassies across the nation was hatched.

Brisbane City Council wanted everything cleared before the Paniyiri Greek Festival this weekend, including the fire.

Go here to see the original:
Anatomy of a protest

Mind, Body and Cancer

PHOENIX, May 16, 2012 (GLOBE NEWSWIRE) -- When it comes to cancer, there are obvious mind-body links. Stress, pessimism and other emotional factors have been proven to play a role, increasing the risk of cancer, metastasis and early mortality. This is a double-whammy for cancer patients, who must overcome anxiety from the moment they are diagnosed. In particular, stress has been shown to depress the immune system, increase inflammation and affect our bodies on the molecular level, even damaging DNA.

In a recent lecture in Phoenix, AZ at the American Academy of Anti-Aging Medicine (A4M) Fellowship, integrative medicine pioneer Isaac Eliaz, M.D., L.Ac. discussed how negative emotions hinder immune response and fuel cancer formation and metastasis. He followed by sharing research on mind-body therapies such as meditation, yoga and Qigong which work to counteract the negative effects of stress and boost health in numerous ways. Highlighting an array of published studies, Dr. Eliaz showed how chronic stress can be deadly to lymphocytes and DNA integrity, and conversely, how mind body therapies and emotional support can ramp up immunity and provide numerous health benefits.

"The contrasts are amazing," says Dr. Eliaz. "Chronic stress significantly reduces the immune response, while something as simple as family support or mindful meditation can boost it just as dramatically."

The negative effects of stress have been studied in a variety of cancers including breast, ovarian, and digestive tract. In one study cited by Dr. Eliaz, breast cancer risk doubled for women after a divorce, separation or the death of their spouse.

In addition to reducing our body's resistance to cancer, stress, depression and isolation also increase metastasis and tumor vascularization. While these facts may be daunting, there are solutions that can make a substantial difference.

In his presentation, Dr. Eliaz discussed a variety of mind-body techniques, including meditation, yoga and Qigong -- an ancient Chinese system of mindful exercises -- that can calm stress and restore the body's healthy balance. In particular, meditation reduces cortisol levels, pro-inflammatory cytokines, systolic blood pressure, anxiety, depression and stress. It also has been proven to increase multiple areas of cognitive function, including information processing, memory and decision making.

"Study after study shows that reducing stress, and its associated negative effects, boosts the immune system and enhances brain function," says Dr. Eliaz.

Yoga fares equally well, helping post-operative breast cancer patients by accelerating healing, reducing hospital stays and enhancing quality of life. The practice has also been shown to reduce the nausea associated with chemotherapy. Qigong has similar benefits.

As a meditation practitioner with over 25 years of experience, Dr. Eliaz has cultivated a deep understanding of the philosophies and application of mindful meditation for healing and personal growth. To integrate practice with theory and research, Dr. Eliaz shared important meditation exercises and take home tools for beginners, to enable participants to experience the benefits of meditation first hand.

"Through all this research, we see one common thread--the calming, healing power of our brains when harnessed through meditation and mind body practice," says Dr. Eliaz. "Simple acts, like breathing mindfully, can have a dramatic effect on all aspects of our being, right down to the molecular level. When practiced regularly, mind body therapies can be powerful tools to help us maintain optimal mental, emotional and physical health."

See the original post:
Mind, Body and Cancer

Brett Tollman Interview at 2012 World Travel and Tourism Council – Video

15-05-2012 05:03 Brett Tollman, chief executive of The Travel Corporation (TTC), showed his support for a global unification of the travel industry at the 2012 World Travel and Tourism Council (WTTC) Global Summit in Tokyo/Sendai. TTC has been a member of the WTTC since 1997, but Brett Tollman (www.bretttollman.biz) has long been an advocate for educating government and industry as to the importance of the tourism industry on global economy, after all, tourism currently employs over 250 million people worldwide, and that number is expected to grow. By uniting under the auspices of the WTTC, TTC and other travel services providers can speak in one voice to educate and influence governments to removing barriers that keep visitors from coming in and out of their countries.

Visit link:

Brett Tollman Interview at 2012 World Travel and Tourism Council - Video

Al Faisaliah Hotel Gains International Recognition at World Travel Awards

Al Faisaliah Hotel, managed by Rosewood Hotels & Resorts, was recognized as “Saudi Arabia’s Leading Hotel” for the second consecutive year, as well as “Middle East’s Leading Luxury City Hotel”.Riyadh, Saudi Arabia (PRWEB) May 15, 2012 In a demonstration of all-round distinction & superiority, Al Faisaliah Hotel, A Rosewood Hotel, scooped two international awards at the annual World Travel Awards ...

More:

Al Faisaliah Hotel Gains International Recognition at World Travel Awards